

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib

Data Article

The differentially mitochondrial proteomic dataset in human ovarian cancer relative to control tissues



Xianquan Zhan^{a,b,c,d,*}, Tian Zhou^{a,b,c}, Na Li^{a,b,c}, Huanni Li^e

^a Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, PR China

^b Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, PR China

^c State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, PR China

^d The Laboratory of Medical Genetics, Central South University, 88 Xiangya Road, Changsha, Hunan 410008, PR China

^e Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China

ARTICLE INFO

Article history: Received 30 August 2017 Received in revised form 21 July 2018 Accepted 9 August 2018 Available online 14 August 2018

ABSTRACT

This data article presents a differentially mitochondrial proteomic dataset in human ovarian cancer tissues relative to control tissues. The mitochondrial samples were prepared from human ovarian cancer and control ovary tissues, and were digested with trypsin. The tryptic peptides from ovarian cancer and control mitochondrial samples were labeled by isobaric tags for relative and absolute quantification (iTRAQ) reagents, followed by strong-cation exchange (SCX) chromatography, liquid chromatography (LC)-tandem mass spectrometry (MS/MS), and bioinformatic analysis. This data article is related to a published article (Li et al., 2018) [1].

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: http://dx.doi.org/10.1016/j.jprot.2017.08.020

E-mail address: yjzhan2011@gmail.com (X. Zhan).

http://dx.doi.org/10.1016/j.dib.2018.08.028

2352-3409/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

^{*} Corresponding author at: Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, PR China.

Subject area More specific subject area	Biological medicine Mitochondrial proteomics
Type of data	Table
How data was acquired	Isobaric tags for relative and absolute quantification (iTRAQ)-labeled samples were mixed and fractionated with strong-cation exchange
	(SCX) chromatography, followed by a 60-min liquid chromatography- tandem mass spectrometry (LC-MS/MS) analysis on a Q Exactive mass spectrometer (Thermo Scientific) that was coupled to Easy nLC
	(Proxeon Biosystems, now Thermo Fisher Scientific) for each fraction.
Data format	PDF file (Raw)
Experimental factors	Mitochondria were separated and purified from human ovarian
-	cancer tissues and control ovary tissues.
Experimental features	A. Mitochondrial samples were digested with trypsin.
	B. The tryptic peptides were labeled with iTRAQ reagents.
	c. The iTRAQ labeled samples were mixed equally.
	D. The mixed iTRAQ samples were fractionated with SCX.
	E. Each fractionation was analyzed with LC-MS/MS.
	F. Database search and data analysis to determine each differentially expressed protein.
Data source location	Xiangya Hospital, Central South University, Hunan 410008 PR China
Data accessibility	Data is within this article, provided as supplementary file.
Related research article	N. Li, X.H. Zhan, X. Zhan. The IncRNA SNHG3 regulates energy meta-
	bolism of ovarian cancer by an analysis of mitochondrial proteomes.
	Gynecologic Oncology, 2018, 150 (2): 343–354. http://dx.doi.org/10.1016/ j.ygyno.2018.06.013 [1]

Specifications Table

Value of the data

- Mitochondria were separated and purified from ovarian cancer tissues and control ovary tissues, with high purity.
- Dataset includes 1198 differentially expressed proteins identified from ovarian cancer and control mitochondrial samples.
- Relative abundance (ratio of cancer to control), statistically significant *p*-value, peptide spectrum matches (PSMs), and database accession number might be useful for other researchers to select the method of choice according to the target of interests.

1. Data

Differentially expressed proteins (DEPs) identified between ovarian cancer and control mitochondrial samples are reported, with the corresponding PSMs, relative abundance (ratio of cancer to control), statistically significant *p*-value, and database accession number. Data are provided as supplementary file (Supplementary Table 1).

2. Experimental design, materials and methods

2.1. Sample preparation

Ovarian tissue samples, which include seven ovarian cancers and eleven control ovaries with benign gynecologic diseases, were collected from Department of Gynecology, Xiangya Hospital, which was approved by the Xiangya Hospital Medical Ethics Committee of Central South University, China. Mitochondria were prepared, their proteins were extracted, according to the protocols [1–3].

2.2. iTRAQ labeling and SCX-LC-MS/MS analysis

iTRAQ-labeling technology integrated with SCX-LC-MS/MS analysis [4,5] were performed to identify DEPs in extracted mitochondrial protein samples from ovarian cancers and controls. In brief, mitochondrial proteins were digested with trypsin, and the tryptic peptides were labeled with the iTRAQ reagents according to the manufacturer's instructions (Applied Biosystems). The iTRAQ-labeled peptides were equally pooled and fractionated by SCX. Each collected fractionation was subjected to a 60-min LC-MS/MS analysis with a Q Exactive mass spectrometer (Thermo Scientific) equipped with Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific). MS/MS data were used to identify proteins with MASCOT engine (Matrix Science, London, UK; version 2.2) embedded into Proteome Discoverer 1.4. Mitochondrial DEPs were determined with the intensity difference of iTRAQ reporter ions [1].

2.3. Bioinformatic analysis

DAVID Bioinformatics Resources 6.7 (https://david.abcc.ncifcrf.gov/home.jsp) was used to analyze the mitochondrial DEPs, including biological process, cellular compartment, molecular function, and KEGG pathway enrichments [6].

Acknowledgements

This work was supported by the Xiangya Hospital Funds for Talent Introduction, China (to XZ); and the grants from China "863" Plan Project (Grant no. 2014AA020610-1 to XZ), the National Natural Science Foundation of China (Grant nos. 81272798 and 81572278 to XZ), and the Hunan Provincial Natural Science Foundation of China (Grant no. 14JJ7008 to X)

Transparency document. Supplementary material

Transparency document associated with this article can be found in the online version at https://doi.org/10.1016/j.dib.2018.08.028.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.dib.2018.08.028.

References

N. Li, X.H. Zhan, X. Zhan, The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes, Gynecol. Oncol. 150 (2018) 343–354.

- [2] X.S. Jiang, H. Zhou, L. Zhang, Q.H. Sheng, S.J. Li, L. Li, P. Hao, Y.X. Li, Q.C. Xia, J.R. Wu, R. Zeng, A high-throughput approach for subcellular proteome: identification of rat liver proteins using subcellular fractionation coupled with two-dimensional liquid chromatography tandem mass spectrometry and bioinformatic analysis, Mol. Cell. Proteom. 3 (2004) 441–455.
- [3] M.J. Schonenberger, W.J. Kovacs, Isolation of peroxisomes from mouse brain using a continuous Nycodenz gradient: a comparison to the isolation of liver and kidney peroxisomes, Method. Mol. Biol. 1595 (2017) 13–26.
- [4] T. Cai, B. Wu, X. Tang, Z. Zhou, J. Yang, R. Ke, X. Mu, iTRAQ-based proteomic analysis reveals possible target-related proteins and signal networks in human osteoblasts overexpressing FGFR2, Proteome Sci. 16 (2018) 12.
- [5] Y. Zhu, H. Xu, H. Chen, J. Xie, M. Shi, B. Shen, X. Deng, C. Liu, X. Zhan, C. Peng, Proteomic analysis of solid pseudopapillary tumor of the pancreas reveals dysfunction of the endoplasmic reticulum protein processing pathway, Mol. Cell Proteom. 13 (2014) 2593–2603.
- [6] X. Wang, T. Guo, F. Peng, Y. Long, Y. Mu, H. Yang, N. Ye, X. Li, X. Zhan, Proteomic and functional profiles of a folliclestimulating hormone positive human nonfunctional pituitary adenoma, Electrophoresis 36 (2015) 1289–1304.